Akari Therapeutics (AKTX) Cash from Financing Activities (2014 - 2026)

Akari Therapeutics (AKTX) reported Cash from Financing Activities of $53000.0 for Q1 2026, down 97.52% on a YoY basis from $2.1 million in Q1 2025, and down 99.08% sequentially from $5.8 million in Q4 2025.

Akari Therapeutics (AKTX) Cash from Financing Activities (2014 - 2026) Analysis & Trends

Akari Therapeutics (AKTX) has 8 years of Cash from Financing Activities data on file, last reported at $53000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Cash from Financing Activities fell 97.52% year-over-year to $53000.0; the trailing twelve-month figure through Mar 2026 stood at $11.1 million (down 4.45% YoY), and the FY2025 full-year result was $13.2 million, up 19.87% from the prior year.
  • Cash from Financing Activities retreated to $53000.0 in Q1 2026, from $5.8 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $7.8 million in Q2 2024 to a low of -$443000.0 in Q3 2024.
  • A 4-year average of $2.6 million and a median of $2.1 million in 2024 frame the typical range for Cash from Financing Activities.
  • Across the five-year window, Cash from Financing Activities jumped 2567.7% in 2024 and slumped 97.52% in 2026, its largest moves.
  • Tracing AKTX's Cash from Financing Activities over 4 years: stood at $3.5 million in 2023, then sank by 38.75% to $2.2 million in 2024, then soared by 167.41% to $5.8 million in 2025, then slumped by 99.08% to $53000.0 in 2026.
  • Business Quant data shows AKTX's Cash from Financing Activities at $53000.0 in Q1 2026, $5.8 million in Q4 2025, and $1.9 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - 30.14 Mn
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - 53,000.00
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 68.63 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -538.80 Mn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -802.20 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - 238.74 Mn
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn 15.71 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 53,000.00
Mar 31, 2026 53,000.00
Dec 31, 2025 5.76 Mn
Dec 31, 2025 5.76 Mn
Sep 30, 2025 1.90 Mn
Sep 30, 2025 1.90 Mn
Jun 30, 2025 3.38 Mn
Jun 30, 2025 3.38 Mn
Mar 31, 2025 2.13 Mn
Mar 31, 2025 2.13 Mn
Dec 31, 2024 2.15 Mn
Dec 31, 2024 2.15 Mn
Sep 30, 2024 -443,000.00
Sep 30, 2024 -443,000.00
Jun 30, 2024 7.76 Mn
Jun 30, 2024 7.76 Mn
Mar 31, 2024 1.51 Mn
Mar 31, 2024 1.51 Mn
Dec 31, 2023 3.52 Mn
Dec 31, 2023 3.52 Mn